Clinical trial

Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

NCT07241819

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2025-11-30

PhasePHASE2

Study timeline

Study start (estimated)2025-11-30Date precision: day

Registry last updated2025-11-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

II-IIIB (T3N2) Resectable Non-small Cell Lung Cancerunresolved

Perioperativeunresolved

Interventions

Ivonescimab/surgeryCOMBINATION_PRODUCT

Ivonescimab/chemotherapy/surgeryCOMBINATION_PRODUCT

Sponsors & collaborators

Peking University Cancer Hospital & Institutelead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07241819 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.